Vogt–Koyanagi–Harada disease: diagnosis and treatments update

  title={Vogt–Koyanagi–Harada disease: diagnosis and treatments update},
  author={M Bordaberry},
  journal={Current Opinion in Ophthalmology},
  • M. Bordaberry
  • Published 1 November 2010
  • Medicine
  • Current Opinion in Ophthalmology
Purpose of review To review current advances in the diagnosis and therapy of Vogt–Koyanagi–Harada (VKH) disease. Recent findings A new T-cell subset (Th17) may play an important role in the initiation and maintenance of inflammatory disease when stimulated by the interleukin (IL)-23, thus producing IL-17. Recent developments of new imaging techniques, such as high-resolution optical coherence tomography 3 scanner (OCT3), have allowed greater accuracy in VKH disease diagnosis. The OCT3… 
[Vogt-Koyanagi-Harada disease].
Major review Vogt-Koyanagi-Harada disease
Ocular coherence tomography has replaced other imaging modalities in the diagnosis of acute and chronic Vogt-Koyanagi-Harada disease by revealing exudative detachments of the retina in the acute stage, along with choroidal thickening and demonstrating choroid thinning in the chronic stage.
Vogt-Koyanagi-Harada disease
Vogt–Koyanagi–Harada disease
The mainstay of treatment for acute VKH relies on prompt systemic corticosteroid therapy initiated as a high dose and then tapered gradually, and other immunosuppressants may be given as second-line or, in selected cases, as first-line therapy.
Vogt-Koyanagi-Harada disease: Novel insights into pathophysiology, diagnosis and treatment
Novel treatment regimen of Vogt–Koyanagi–Harada disease with a reduced dose of corticosteroids combined with immunosuppressive agents
A reduced dose of corticosteroids combined with immunosuppressive agents effectively controlled the intraocular inflammation and improved visual acuity in most Chinese VKH patients.
Microvasculature Features of Vogt-Koyanagi-Harada Disease Revealed by Widefield Swept-Source Optical Coherence Tomography Angiography
The quantifiable and layer-specific information from OCTA allows for the identification of sensitive and specific imaging markers for prognosis and treatment guidance, highlighting WSS-OCTA as a promising modality for the clinical management of VKH disease.
Treatment of Probable Vogt-Koyanagi-Harada with Single Intravitreal Triamcinolone Acetonide
Intravitreal steroids can be considered as treatment in VKH in situations where systemic corticosteroids are contraindicated, such as patients with a history of poorly controlled diabetes, and in some patients short-term treatment of VKH with local Corticosteroid may result in long-term visual stability.
Vogt-Koyanagi-Harada syndrome: Experience in a Belgian university hospital and review of the literature
The Vogt-Koyanagi-Harada syndrome is a rare, multisystem disorder, characterized by bilateral uveitis and variable neurologic, auditory and skin symptoms, and if treated correctly, VKHS has a favorable prognosis.
Clinical Features of Recurred Vogt-Koyanagi-Harada Syndrome during Oral Steroids Tapering Therapy
Serous retinal detachment can recur during oral steroid tapering after high-dose intravenous steroid treatment in patients with Vogt-Koyanagi-Harada syndrome suggesting that the height of the subretinal fluid at the fovea and central subfield thickness before treatment are factors associated with recurrence.


New insights into Vogt-Koyanagi-Harada disease.
The aim of this paper is to review the latest research results on Vogt-Koyanagi-Harada disease pathogenesis and chronic/convalescent stages, which may help to better understand this potentially blinding disease and to improve its treatment.
[Adalimumab therapy for Vogt-Koyanagi-Harada syndrome].
The efficiency and advantages of the new anti-TNF therapy with adalimumab in the VogtKoyanagi Harada Harada (VKH) syndrome, an inflammatory pathology for which the results of the above drug have not yet been described are reported.
Vogt-Koyanagi-Harada syndrome: a rheumatologic perspective
The success in preserving the vision of VKH syndrome patients hinges on early diagnosis and aggressive treatment that includes immunomodulatory therapy, and as a result ophthalmologists are increasingly referring such patients to specialists.
Edema of the Photoreceptor Layer in Vogt-Koyanagi-Harada Disease Observed Using High-Resolution Optical Coherence Tomography
High resolution OCT findings indicate that edema of the photoreceptor layer participates in the development of a cystoid space in the photOREceptor layer, which was related to poor initial visual acuity, but not to finalVisual acuity.
Suboptimal therapy controls clinically apparent disease but not subclinical progression of Vogt-Koyanagi-Harada disease
Submaximal doses of inflammation suppressive therapy are sufficient to suppress clinically apparent disease but not the underlying lesion process, which explains the propensity for sunset glow fundus in seemingly controlled disease.
Presumed Vogt-Koyanagi-Harada disease with unilateral ocular involvement: report of three cases
The clinical and laboratory features of all three patients were typical of VKH disease except for the unilateral involvement, and it is important for ophthalmologists to recognize unilateralVKH disease, even though it is a rare clinical variant of the disease.
Management of ocular complications of Vogt-Koyanagi-Harada syndrome
Use of ocular invasive treatment modalities in Vogt-Koyanagi-Harada Syndrome only if the disease progression cannot be controlled is recommended, and if systemic medications fail to stop the progression of the disease activity, subtenon injections may be considered before intraocular treatmentmodalities.